CLINICAL PROFILE, PRESCRIPTION PATTERNS, AND ADVERSE DRUG REACTIONS IN PATIENTS WITH VITILIGO: A PROSPECTIVE STUDY
Objectives: The objectives of the study were to assess clinical profile (age of onset, age of presentation, gender, site of involvement, severity (stage), type of vitiligo, triggering factors, and associated diseases), prescription patterns (monotherapy, combination therapy, oral, topical, and therapeutic categories of drugs prescribed) and to monitor and report adverse drug reactions (based on World Health Organization [WHO] causality assessment scale) in vitiligo patients.
Methods: A hospital-based prospective observational study was carried out by evaluating and assessing the clinical profile and prescription patterns of 85 patients who attended dermatology venereology and leprosy (DVL) outpatient department at Sri Padmavathi Medical College for Women, SVIMS, Tirupati, over a period of 6 months from June 2019 to December 2019.
Results: In our study, forty four (51.77%) patients were female, vitiligo vulgaris is the most common morphological type observed in twenty seven (31.76%) patients. 31–50 years was the predominant age group. The mean age of onset and presentation was 38.35 (standard deviation of 18.37) and 43.27 (standard deviation of 17.96) years, respectively. Forty-one (48.23%) patients were having Stage 1 vitiligo. Fifty (58.85%) patients were having vitiligo at more than 1 site. Twelve (14.11%) patients were having a positive family history of vitiligo. Thirty-seven (43.53%) patients had triggering factors. Associated diseases were found in thirty (35%) patients. Combination therapy was given to sixty one (71.77%) patients. Topical medications were given to fifty two (61.18%) patients. During the study, we did not have a single patient complaining of any adverse drug reaction.
Conclusion: Longer the time after appearance of vitiligo, lesser the number of patients attending follow-up. If vitiligo is diagnosed at the earliest stage, more are the chances for complete repigmentation. Patients with a poor economic background are less bothered about their skin condition and are not using medications properly.
2. Bishnoi A, Parsad D. Clinical and molecular aspects of vitiligo treatments. Int J Mol Sci 2018;19:1509.
3. Falabella R, Barona MI. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res 2009;22:42-65.
4. Felsten LM, Alikhan A, Petronic V Rosic. Vitiligo: A comprehensive overview Part II: Treatment options and approach to treatment. J Am Acad Dermatol 2011;65:493-514.
5. Taieb A, Alomar A, Böhm M, Dell’anna ML, De Pase A,Eleftheriadou V, et al. Guidelines for the management of vitiligo: The European dermatology forum consensus. Br J Dermatol 2013;168:5-19.
6. Mandel AS, Haberman HF, Pawlowski D, Goldstein E. Non-PUVA nonsurgical therapies for vitiligo. Clin Dermatol 1997;15:907-19.
7. Kanwar AJ, Kumaran MS. Childhood vitiligo: Treatment paradigms. Indian J Dermatol 2012;57:466-74.
8. Falabella R. Surgical approaches for stable vitiligo. Dermatol Surg 2005;31:1277-84.
9. Boone B, Ongenae K, Van Geel N, Vernijns S, De Keyser S, Naeyaert JM, et al. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007;17:55-61.
10. Natta R, Somsak T, Wisuttida T, Laor L. Narrowband ultraviolet B radiation therapy for recalcitrant vitiligo in Asians. J Am Acad Dermatol 2003;49:4736.
11. Fatani MI, Aldhahri RM, Otaibi HO, Kalo BB, Khalifa MA. Acknowledging popular misconceptions about vitiligo in Western Saudi Arabia. J Dermatol Dermatol Surg 2016;20:27-31.
12. Chinthaamani KP. An epidemiological study of vitiligo in an urban city hospital. Acta Sci Med Sci 2018;24:07-12.
13. Agarwal S, Ojha A, Gupta S. Profile of vitiligo in kumaun region of Uttarakhand, India. Indian J Dermatol 2014;59:209.
14. Mahajan VK, Vashist S, Chauhan PS, Mehta KIS, Sharma V, Sharma A. Clinico-epidemiological profile of patients with vitiligo: A retrospective study from a tertiary care center of north India. Indian Dermatol Online J 2019;10:38-44.
15. Vora RV, Patel BB, Chaudhary AH, Mehta MJ, Pilani AP. A clinical study of vitiligo in a rural set up of Gujarat. Indian J Community Med 2014;39:143-46.
16. Wazir SM, Paracha MM, Khan SU. Efficacy and safety of topical mometasone furoate 0.01% vs. tacrolimus 0.03% and mometasone furoate 0.01%in vitiligo. J Pak Assoc Dermatol 2016;20:89-92.
17. Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate, and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006;20:269-73.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.